{"id":"W4283771201","doi":"10.1016/s1470-2045(22)00343-6","title":"Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations – Authors' reply","year":2022,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Trabectedin; Topotecan; Oncology; Medicine; Ovarian cancer; Internal medicine; Regimen; Olaparib; BRCA mutation; Chemotherapy; Cancer; Pathology; Sarcoma; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002614422,0.0007495257,0.001714008,0.0009075912,0.00301088,0.003687199,0.001769269,0.07328597,0.007048798],"category_scores_gemma":[0.02041866,0.0009194762,0.001309574,0.0007682431,0.002797606,0.003007753,0.002050307,0.04364851,0.005165724],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00355096,"about_ca_system_score_gemma":0.003060552,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004254979,"about_ca_topic_score_gemma":0.005912204,"domain_scores_codex":[0.9971504,0.0009090385,0.0003112689,0.0003500402,0.0007312504,0.000548017],"domain_scores_gemma":[0.9921457,0.004826753,0.0006273597,0.000214357,0.0009118825,0.001273913],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00007750667,0.0000180014,0.0005723235,0.0000559558,0.00002877552,0.001547458,0.0001116827,0.00006739338,0.0001269734,0.001547836,0.9911772,0.004668969],"study_design_scores_gemma":[0.0002961919,0.0001177302,0.001322612,0.0004154886,0.00007507476,0.002597041,0.0004687308,0.0004058449,0.0002753017,0.007453024,0.9864722,0.0001007112],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"editorial","genre_scores_codex":[0.000272621,0.001712699,0.00003029027,0.9765911,0.02014322,0.000006189202,0.00005240057,0.00001184572,0.001179562],"genre_scores_gemma":[0.002846824,0.0009842002,0.00005795937,0.9596846,0.03291566,0.00002398033,0.00003670549,0.00001481858,0.003435176],"genre_candidate":"editorial","genre_consensus":null,"teacher_disagreement_score":0.07328597,"threshold_uncertainty_score":0.02576417,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06730842307923487,"score_gpt":0.3634795755095666,"score_spread":0.2961711524303318,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}